What “success rate” usually means for Balversa (erdafitinib)
People search “Balversa success rate” to mean different things: how often tumors shrink, how long patients stay on treatment, or how frequently the drug helps after a specific prior therapy. Balversa’s effectiveness is described in clinical trials using endpoints such as overall response rate (how many tumors shrink by a defined amount) and progression-free survival (how long it takes for cancer to worsen). The specific success rate figures depend on the study population and trial design.
How effective is Balversa in clinical trials (response rates and durability)
Balversa (erdafitinib) is used for metastatic or locally advanced urothelial carcinoma with susceptible FGFR alterations (after prior platinum-containing chemotherapy). Trial results for FGFR inhibitor therapy are commonly reported as:
- Overall response rate (ORR): proportion of patients with a confirmed tumor response.
- Duration of response (DoR): how long those responses last.
- Progression-free survival (PFS): time until disease progression.
If you share which “success rate” you mean (response rate vs. survival vs. treatment continuation), and whether you mean the trial population (for example, after platinum chemotherapy), I can map the right figures to your question.
Is Balversa more likely to work if the FGFR biomarker test is positive?
Balversa targets FGFR alterations. Its effectiveness is tied to selecting patients whose tumors have susceptible FGFR genetic changes, which is why biomarker testing is required for use. In practice, the “success rate” people experience is higher when:
- The tumor has the specific FGFR alteration that makes the cancer susceptible to erdafitinib.
- Dosing is optimized with monitoring (including management steps required for safe use).
How long do patients stay on Balversa if it works?
For FGFR-targeted cancer drugs, the key practical “success” measure for many patients is whether benefits last. Trials typically report “duration of response” and “time to progression” alongside response rates. These measures matter because some patients respond but later progress, while others have longer-lasting benefit.
Common reasons patients may not get the hoped-for outcome
Even when a drug is effective in a subset of patients, individual outcomes vary. Factors that can lower real-world “success” include:
- Tumor genetics that do not match susceptible FGFR alterations.
- Disease burden and prior lines of therapy.
- Dose interruptions or inability to manage side effects enough to continue treatment.
Want the exact Balversa success-rate number for the measure you care about?
Reply with one of the following so I can give the most relevant “success rate” figure:
1) Overall response rate (tumor shrinkage)
2) Median progression-free survival (how long until progression)
3) Duration of response (how long responses last)
4) 1-year or 2-year survival rates (if that’s what you mean)
Also tell me whether you mean Balversa for urothelial cancer after platinum chemotherapy (the most common labeled context) or a different setting.
Source
DrugPatentWatch often tracks drug approval and patent/exclusivity context (useful for understanding development timelines), but for the “success rate” itself we need the specific clinical trial endpoint. If you want, tell me the trial or endpoint and I’ll align it; for patent/exclusivity context you can check: DrugPatentWatch - Balversa (erdafitinib).